- Home
- GECC vs SEER Comparison
GECC vs SEER Comparison
Compare GECC & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.79
Company Overview
Basic Information| Metric | GECC | SEER |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.8M | 111.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GECC | SEER |
|---|---|---|
| Price | $4.75 | $1.79 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | 115.6K | ★ 366.0K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 24.34% | N/A |
| EPS Growth | N/A | ★ 9.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,578,000.00 |
| Revenue This Year | $6.15 | $2.14 |
| Revenue Next Year | N/A | $25.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.99 |
| 52 Week Low | $4.80 | $1.62 |
| 52 Week High | $11.45 | $2.41 |
Technical Indicators
Market Signals| Indicator | GECC | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 18.27 | 43.62 |
| Support Level | N/A | $1.71 |
| Resistance Level | $7.16 | $1.97 |
| Average True Range (ATR) | 0.29 | 0.08 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 7.07 | 25.58 |
Price Performance
Historical Comparison GECC
SEER
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.